HomeFilePharmacology

Pharmacology

View Category

Antiplatelet

Antiaggregation vs. Anticoagulation after Peripheral PCI

The truth is this question has no clear answer and what with do with peripheral stenting is...
solaci -
Learn More
Antiplatelet

Webinar SOLACI – 29/05 – Approach to Antiplatelet Therapy in Acute Coronary Syndrome

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be...
solaci -
Learn More
Pharmacology

Cerebrovascular Events After TAVR May Be Especially Serious

Stroke events do not seem to be related to valve thrombosis or structural degeneration, but to a...
solaci -
Learn More
Coronary disease

ECS Guidelines for COVID-19 Management

One of the first statements in this document points out these are not “regular guidelines” developed after...
solaci -
Learn More
Acute coronary syndromes

Are Non-Culprit Lesions Really Innocent?

In recent times, a lot has been said about reducing the duration or intensity of antiplatelet therapy...
solaci -
Learn More
Other

A New Molecule to Prevent Contrast-Induced Kidney Injury

Administrating Recombinant Human C1-Esterase-Inhibitor (rhC1INH) before coronary angiography might mitigate contrast induced kidney injury. In addition, it...
solaci -
Learn More
Coronary disease

Cardiology in Times of Coronavirus: The Perfect Storm

Since January 2020, the COVID-19 infection has spread from China to the rest of the world. The...
solaci -
Learn More
Acute coronary syndromes

Virtual ACC 2020 | TICO: Ticagrelor Monotherapy in Acute Coronary Syndromes

Switching to ticagrelor monotherapy after 3 months of dual antiplatelet therapy reduces major bleeding without paying a price...
solaci -
Learn More